Journal of cardiac surgery · 1994
Mitral valve balloon dilatation: long-term results.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bittl J A
Аннотация
BACKGROUND: Although initial success rates for mitral valve balloon dilatation are currently about 85%, the procedure remains investigational and is not performed in many centers because the procedure is technically challenging and has uncertain long-term results.
AIM: The purpose of this report is to identify the predictors of long-term results after mitral valve balloon dilatation.
RESULTS: At 30-day follow-up of 738 patients treated at 24 centers (mean age 54 years), 4% of patients required mitral valve surgery, 3% had died, and 83% had their overall condition improved. At 2-month and 1-year follow-up of 17 patients treated at one center, quality of life showed sustained improvement as measured by the Sickness Impact Profile. At 5-year follow-up of 146 patients treated at a single center (mean age 59 years), overall survival was 76% and event-free survival was 51%. At 5-year follow-up of a younger group of 350 patients (mean age 46 years), overall survival was 94% and event-free survival was 85%. Predictors of survival after mitral balloon dilatation included age and baseline New York Heart Association functional class. Predictors of restenosis included the presence of valve calcification and leaflet thickening.
CONCLUSIONS: Mitral valve balloon dilatation has good long-term outcome for selected patients with mitral stenosis. The long-term outcome after this procedure can be predicted from baseline clinical and valvular characteristics.
AIM: The purpose of this report is to identify the predictors of long-term results after mitral valve balloon dilatation.
RESULTS: At 30-day follow-up of 738 patients treated at 24 centers (mean age 54 years), 4% of patients required mitral valve surgery, 3% had died, and 83% had their overall condition improved. At 2-month and 1-year follow-up of 17 patients treated at one center, quality of life showed sustained improvement as measured by the Sickness Impact Profile. At 5-year follow-up of 146 patients treated at a single center (mean age 59 years), overall survival was 76% and event-free survival was 51%. At 5-year follow-up of a younger group of 350 patients (mean age 46 years), overall survival was 94% and event-free survival was 85%. Predictors of survival after mitral balloon dilatation included age and baseline New York Heart Association functional class. Predictors of restenosis included the presence of valve calcification and leaflet thickening.
CONCLUSIONS: Mitral valve balloon dilatation has good long-term outcome for selected patients with mitral stenosis. The long-term outcome after this procedure can be predicted from baseline clinical and valvular characteristics.